预约演示
更新于：2026-09-08
Vildagliptin
维格列汀
更新于：2026-09-08
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 欧盟 (2007-09-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H25N3O2 |
InChIKeySYOKIDBDQMKNDQ-XWTIBIIYSA-N |
CAS号274901-16-5 |
关联
299
项与 维格列汀 相关的临床试验CTRI/2026/06/112499
Comparison of Dasatinib plus DPP IV inhibitor Vildagliptin versus Dasatinib monotherapy in reduction of peripheral blood leukemic stem cells in chronic myeloid leukemia: a randomized, exploratory pilot study
CTRI/2026/04/109697
Active post marketing surveillance study to evaluate the safety and efficacy of Vildagliptin sustained release tablets 100 mg. - NIL
NCT06951334
Clinical Trial of Vildagliptin in Early Parkinson's Disease
100 项与 维格列汀 相关的临床结果
登录后查看更多信息
100 项与 维格列汀 相关的转化医学
登录后查看更多信息
100 项与 维格列汀 相关的专利（医药）
登录后查看更多信息
1,784
项与 维格列汀 相关的文献（医药）2026-10-01COMPUTATIONAL BIOLOGY AND CHEMISTRY
Machine learning-assisted and simulation-based elucidation of phytochemical dipeptidyl peptidase-4 inhibitors towards safer therapeutics for diabetes
Article
作者: Sinha, Prashasti ; Trivedi, Ravi ; Kumar, Manish
A global problem with Diabetes Mellitus (type 2) is the disruption of insulin release as well as glucose regulation. The Dipeptidyl Peptidase-4 (DPP-4) is responsible for breaking down incretin hormone; therefore, it has an indirect effect on decreasing insulin release. Synthetic inhibitors of DPP-4 are clinically effective; however, due to the many negative side effects associated with them, alternative options are being explored that are much safer. Using an integrated computational pipeline combining cheminformatics-driven chemical space analysis, machine learning-assisted rescoring, ADMET filtering, molecular docking, molecular dynamics (MD) simulations, and systems-level pathway analysis to identify promising phytochemicals as DPP-4 inhibitors. A library of 250 phytochemicals that had been identified as possessing antidiabetic properties was obtained from public databases and then examined using UMAP and PCA so that structural diversity could be determined. Distinct clusters of similar chemical structures were identified using this analysis, and the top 20 compounds identified underwent evaluation of their ADMET properties through the use of SwissADME, pkCSM and admetSAR to confirm that they exhibited appropriate pharmacokinetic and toxicology profiles. Through protein docking with DPP-4 (PDB ID: 6B1E), coumarin, eugenol and cinnamic acid were highlighted as having a high binding affinity when compared to the known inhibitor Vildagliptin. The stability of these complexes was supported by using 500 ns MD simulations and MM/PBSA calculations. In addition to the molecular information, the results of the protein interaction and pathway enrichment analysis indicated that DPP-4 has many functions related to the regulation of insulin secretion and inflammatory processes through a complex network. Therefore, these studies support the use of phytochemical compounds as safe DPP-4 Inhibitors, and offer a new approach for rapid identification of plant-derived compounds for the treatment of T2DM.
2026-09-01Integrative Medicine Research
Ameliorative effects of Wiryeongtang (herbal medicine) on cardiorenal complications via modulation of inflammatory and fibrotic responses in diabetic mice
Article
作者: Lee, Ho Sub ; Park, Sung Joo ; Yang, Yun Jeong ; Yoon, Jung Joo ; Tai, Ai Lin ; Kim, Hye Yoom
Background:
Diabetes causes cardiorenal complications characterized by inflammation, fibrosis, and metabolic dysfunction. Wiryeongtang (WRT), a traditional herbal formula, has shown potential in alleviating metabolic disorder-related complications. This study aimed to investigate the protective effects of WRT on cardiorenal complications in diabetic mice.
Methods:
Four groups were studied: a non-diabetic control (db/m), an untreated diabetic group (db/db), a vildagliptin-treated group (50 mg/kg/day) as a positive control, and a WRT-treated group (200 mg/kg/day). Metabolic parameters, including plasma blood glucose, lipid accumulation, and oral glucose tolerance, were measured. Renal histology was assessed for glomerulosclerosis, mesangial matrix expansion, and fibrosis. Cardiac tissues were examined for hypertrophy, fibrosis, and inflammation. Apoptotic markers (caspase-3, caspase-9, Bcl-2, and Bax) were also measured.
Results:
WRT significantly reduced plasma blood glucose levels and lipid accumulation in db/db mice and improved oral glucose tolerance and insulin resistance. WRT reduced glomerulosclerosis, mesangial matrix expansion, and fibrosis markers in the kidneys. WRT also mitigated diabetes-induced cardiac dysfunction and histopathological changes, including hypertrophy, fibrosis, and inflammation. Additionally, WRT downregulated apoptotic markers (caspase-3 and caspase-9) while increasing the Bcl-2/Bax ratio.
Conclusions:
The findings suggest that WRT may serve as a potential therapeutic agent for managing cardiorenal complications associated with type 2 diabetes. It alleviated hyperglycemia, improved insulin sensitivity, and reduced inflammation and fibrosis in both cardiac and renal tissues through anti-apoptotic and anti-fibrotic mechanisms.
2026-06-18NATURAL PRODUCT RESEARCH
Bio-standardization and development of a unique polyherbal formulation with dipeptidyl peptidase -IV inhibitory activity for type 2 diabetes mellitus
Article
作者: Durgaprasad Tiwari, Devkumar ; Dhanawane, Ujwala ; Mohanty, Ipseeta Ray
Medicinal herbs may provide an alternative source of Dipeptidyl peptidase -IV (DPP-IV) Inhibitors, particularly in light of mounting evidence of high costs and adverse drug reactions associated with synthetic DPP-IV Inhibitors. DPP-IV inhibitory activity of medicinal plants Commiphora mukul, Terminalia arjuna and Phyllanthus emblica was elucidated in previous investigations from our lab. The goal of this work was to develop a polyherbal tablet including these medicinal plants with DPP-IV inhibitory action, conduct bio-standardization investigations, and test its anti-diabetic benefits in the streptozotocin model of Type 2 diabetes. A high-performance thin-layer chromatography technique was developed and validated in terms of linearity, accuracy, precision, repeatability, the limit of detection, and the limit of quantification for the bio-standardization of polyherbal combinations. Polyherbal combination's demonstrated significant DPP-IV inhibitory activity. It was interesting to note that in the Type II diabetes experimental model, the polyherbal combination showed antidiabetic efficacy equivalent to that of the synthetic DPP-IV inhibitor Vildagliptin, which is used in clinical settings.
100 项与 维格列汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 欧盟 | 2007-09-25 | |
| 2型糖尿病 | 冰岛 | 2007-09-25 | |
| 2型糖尿病 | 列支敦士登 | 2007-09-25 | |
| 2型糖尿病 | 挪威 | 2007-09-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性心肌梗塞 | 临床3期 | 葡萄牙 | 2014-11-18 | |
| ST段抬高心肌梗死 | 临床3期 | 葡萄牙 | 2014-11-18 | |
| 1型糖尿病 | 临床3期 | 巴西 | 2014-03-01 | |
| 胰岛素抵抗 | 临床3期 | 英国 | 2010-05-01 | |
| 微血管疾病 | 临床3期 | 英国 | 2010-05-01 | |
| 低血糖 | 临床3期 | 瑞士 | 2006-09-01 | |
| 葡萄糖耐受不良 | 临床3期 | 美国 | 2005-10-01 | |
| 糖尿病前期 | 临床3期 | 美国 | 2005-04-01 | |
| 高血糖 | 临床3期 | 瑞士 | 2004-10-01 | |
| 周围神经系统疾病 | 临床2期 | 法国 | 2010-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 222 | 醖簾範願艱糧齋艱廠餘(蓋遞憲蓋觸繭獵遞憲簾) = almost 300% rise in creatinine and 140% fall in eGFR were noted in the vildagliptin recipients 網壓襯觸醖窪鏇鏇網願 (簾鹽襯齋襯積醖夢糧獵 ) 更多 | 积极 | 2025-07-01 | |||
N/A | - | 憲選蓋衊鹹醖網淵顧願(獵鬱鬱鹽觸築築獵餘範) = Three mild hypoglycemic events were reported with the starting dose 網襯齋願簾餘網觸鏇艱 (選淵齋積獵築艱衊築簾 ) | - | 2024-06-14 | |||
临床4期 | - | 鑰壓蓋襯蓋構餘積衊襯(築網壓選窪艱繭鬱鑰製) = common reductions 鬱憲築襯願獵鏇淵觸顧 (網構簾繭膚醖願簾鹽衊 ) | - | 2022-10-01 | |||
临床4期 | 120 | metformin+empagliflozin | 鹹夢窪鏇築鑰鑰範簾糧(觸顧獵廠糧繭獵壓廠簾) = 糧顧範窪鏇膚蓋鏇鹹範 選淵獵廠鑰鏇願製獵構 (醖築糧積觸鏇築廠繭糧, 0.68) | 积极 | 2022-08-17 | ||
metformin+vildagliptin | 鹹夢窪鏇築鑰鑰範簾糧(觸顧獵廠糧繭獵壓廠簾) = 糧鬱蓋鹽簾餘獵觸衊繭 選淵獵廠鑰鏇願製獵構 (醖築糧積觸鏇築廠繭糧, 1.57) | ||||||
临床4期 | 346 | Pioglitazone 30mg | 繭選選淵鏇築齋餘壓鹹(餘艱構淵壓膚憲夢醖淵) = 憲遞網願鏇製憲醖積觸 網壓簾鬱齋膚淵襯淵鹽 (觸願齋鹹膚製觸製夢鑰 ) | - | 2022-01-01 | ||
临床4期 | 80 | 壓蓋齋製範製淵鏇衊齋(衊鹽鑰衊夢網鬱憲繭獵) = 觸壓網築餘積壓廠糧鹽 簾繭衊襯選餘簾醖繭遞 (顧廠醖膚糧窪積築壓願 ) | - | 2020-12-01 | |||
壓蓋齋製範製淵鏇衊齋(衊鹽鑰衊夢網鬱憲繭獵) = 襯淵襯繭餘夢衊廠糧鑰 簾繭衊襯選餘簾醖繭遞 (顧廠醖膚糧窪積築壓願 ) | |||||||
临床4期 | 2,001 | 觸鬱壓鏇顧餘觸網鏇淵(顧繭繭齋糧鏇鹹積鬱鑰): adjusted mean change = 19.23 (95% CI, 8.42 ~ 30.03) | 积极 | 2020-09-24 | |||
临床4期 | 2型糖尿病 GLP-1 | 15 | 淵蓋鏇鏇獵範遞鏇築鹹(壓鹽顧糧願齋簾繭襯襯) = 鏇觸壓窪衊製窪憲衊膚 膚顧齋築鏇範窪餘築網 (簾遞淵鬱鏇憲構觸鏇願 ) | 积极 | 2019-09-19 | ||
Placebo | 淵蓋鏇鏇獵範遞鏇築鹹(壓鹽顧糧願齋簾繭襯襯) = 觸壓夢積範夢壓積鹹憲 膚顧齋築鏇範窪餘築網 (簾遞淵鬱鏇憲構觸鏇願 ) | ||||||
临床4期 | 28 | (Vildagliptin Treatment) | 窪齋艱築觸膚餘醖簾鹹(觸顧憲鹽繭願網鑰糧獵) = 築淵夢積衊範憲簾鏇鹽 構繭膚襯製選簾簾壓醖 (艱醖範鹽衊衊憲鑰夢窪, 2.6) 更多 | - | 2019-05-02 | ||
(Dapagliflozin Treatment) | 窪齋艱築觸膚餘醖簾鹹(觸顧憲鹽繭願網鑰糧獵) = 鏇顧鏇鑰構繭蓋醖衊範 構繭膚襯製選簾簾壓醖 (艱醖範鹽衊衊憲鑰夢窪, 2.7) 更多 | ||||||
N/A | 300 | 網觸獵衊憲蓋膚構蓋憲(構憲願淵鬱窪醖遞艱繭) = 艱鬱憲艱範窪鑰蓋鬱艱 鏇繭壓構遞醖餘鹹淵廠 (襯遞糧製鏇淵鹹鑰餘願, -0.20 ~ -0.90) | - | 2019-04-01 | |||
網觸獵衊憲蓋膚構蓋憲(構憲願淵鬱窪醖遞艱繭) = 願醖願齋願醖獵鹽淵簾 鏇繭壓構遞醖餘鹹淵廠 (襯遞糧製鏇淵鹹鑰餘願, -0.40 ~ -1.40) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用